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CardiomyocyteThe effect of differential signalling by IL-6 and leukaemia inhibitory factor (LIF) which signal by gp130
homodimerisation or LIFRβ/gp130 heterodimerisation on survival and hypertrophy was studied in neonatal
rat cardiomyocytes. Both LIF and IL-6 [in the absence of soluble IL-6 receptor (sIL-6Rα)] activated Erk1/2,
JNK1/2, p38-MAPK and PI3K signalling peaking at 20 min and induced cytoprotection against simulated
ischemia-reperfusion injury which was blocked by the MEK1/2 inhibitor PD98059 but not the p38-MAPK inhib-
itor SB203580. In the absence of sIL-6R, IL-6 did not induce STAT1/3 phosphorylation,whereas IL-6/sIL-6R and LIF
induced STAT1 and STAT3 phosphorylation. Furthermore, IL-6/sIL-6R induced phosphorylation of STAT1 Tyr701
and STAT3 Tyr705 were enhanced by SB203580. IL-6 and pheneylephrine (PE), but not LIF, induced cardiomyocyte
iNOS expression and nitric oxide (NO) production. IL-6, LIF and PE induced cardiomyocyte hypertrophy, but with
phenotypic differences in ANF and SERCA2 expression and myoﬁlament organisation with IL-6 more resembling
PE than LIF. Transfection of cardiomyocytes with full length or truncated chimaeric gp130 cytoplasmic domain/
Erythropoietin receptor (EpoR) extracellular domain fusion constructs showed that the membrane proximal
Box 1 and Box 2 containing region of gp130 was necessary and sufﬁcient for MAPK and PI3K activation; hyper-
trophy; SERCA2 expression and iNOS/NO induction in the absence of JAK/STAT activation. In conclusion,
IL-6 can signal in cardiomyocytes independent of sIL-6R and STAT1/3 and furthermore, that Erk1/2 and
PI3K activation by IL-6 are both necessary and sufﬁcient for induced cardioprotection. In addition,
p38-MAPK may act as a negative feedback regulator of JAK/STAT activation in cardiomyocytes.
© 2013 Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine of the IL-6 family which
is expressed in many cell types and regulates many physiological and
pathophysiological processes including immune system regulation, in-
ﬂammation, wound healing and cell survival [1]. In the heart, IL-6 is
expressed by integral tissue cellular components such as cardiomyocytes,
ﬁbroblasts and vascular endothelial and smooth muscle cells as well as
interstitial macrophages [2,3]. IL-6 receptors consist of a membrane-
tethered gp80 (cognate) or soluble form of the α-ligand-binding do-
main (IL-6Rα or sIL-6Rα). IL-6Rs are expressed primarily in myocardial
interstitial cells such as ﬁbroblasts and monocytes, rather than car-
diomyocytes [3], but are upregulated in cardiomyocytes in response
to activation by pro-inﬂammatory signals such as angiotensin II,
endothelin-1 and noradrenalin as well as mechanical stretch [3–5].epartments of Cardiology and
e, King's College London, 3.38
SE1 9NH, UK. Tel.: +44 020
-ND license. However, recent evidence suggests that a cognate IL-6R is expressed in
adult rat cardiomyocytes [6]. IL-6 plays an important role in myocardial
remodelling whilst other IL-6 family cytokines such as leukaemia inhibi-
tory factor (LIF) and cardiotrophin-1 (CT-1) also elicit survival andhyper-
trophy signalling via LIFRβ in cardiomyocytes [7,8].
IL-6 family cytokines include IL-6, LIF, CT-1, cilliary neurotrophic
factor (CNTF), oncostatin M (OSM), IL-11, IL-27, erythropoietin (EPO)
and others. They utilise type I cytokine receptors which consist of a li-
gand binding α-receptor subunit and a signal transducing β-receptor
subunit containing a cytoplasmic signalling domain. They are type I
membrane proteins with an N-terminal extracellular domain and a sin-
gle membrane-spanning domain. IL-6 family cytokines utilise the com-
mon transmembrane glycoprotein component gp130 which forms all
or part of the signal transducing domain depending on whether the
ligand/receptor induces gp130 homodimerisation (i.e. In the case of
IL-6, IL-11) or a gp130/β-receptor heterodimer (i.e. In the case of LIF,
CT-1 or OSM). Only formation of the gp130 homo- or heterodimer can
induce signalling. IL-6 can induce gp130-dependent signalling via two
modes, either classically by binding to the cognate gp80 IL-6R or via
trans-signalling which utilises the sIL-6R [1,5]. IL-6 trans-signalling
thus allows IL-6 to signal in tissues/cells which do not necessarily ex-
press cognate IL-6R. The receptors themselves do not contain intrinsic
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Janus family kinases, JAK1, JAK2 or Tyk2 which then phosphorylate ty-
rosine residues in the distal cytoplasmic domain of gp130 which in
turn act as docking sites for the SH2 domains of the Signal Transducer
and Activator of Transcription (STAT) family of transcription factors
(typically STATs 1, 3 and 5). Subsequent phosphorylation of STATs then
induces STAT dimerisation and translocation to the nucleus where they
activate gene transcription. Thus JAK/STAT activation is a classical hall-
mark of gp130-dependent cytokine signalling [1,9]. However, IL-6 family
cytokines also activate a full complement of mitogen- and stress-
activated protein kinases (MAPKs/SAPKs), including Erk1/2, JNK1/2 and
p38-MAPK and also the phospho-inositide-3-kinase (PI3K)/Akt (protein
kinase B: PKB) axis [1,10]. MAPK activation is thought to occur primarily
through recruitment of the protein tyrosine phosphatase SHP2 to Tyr757
in the central region of gp130which then recruits Grb2/Shc/Ras/Mek1/2/
Erk1/2 [11]. However, JAK2 can also activate Erk1/2 and PI3K/Akt inde-
pendently of SHP2 [12,13].
The relative contributions of Erk1/2, PI3K/Akt and JAK/STAT
signalling to cardiomyocyte hypertrophy and survival is complex.
Erk1/2 appears to play an important role in regulating hypertrophic
gene expression and aspects of myoﬁlament remodelling, whereas
JAK/STAT activation may be more important in myoﬁlament organi-
sation [7,10,14]. PI3K/Akt plays an important role in adaptive hyper-
trophy [15,16]. Erk1/2 and PI3K play a critical role in cardiomyocyte
survival, since activation by cardiac cytokines IL-6, LIF and CT-1 protects
cardiomyocytes against apoptosis induced by a variety of stressors, in-
cluding the chemotherapeutic agent doxorubicin, angiotensin II and
myocardial injury [8,17–19]. In this study we have explored differences
in signalling between IL-6 and LIF, these two cytokines representing the
two principal different modes of gp130 recruitment, i.e. IL-6-induced
gp130 homodimerisation and LIF-induced gp130/LIFRβ heterodimer-
isation. Despite the reported lack of basal cognate IL-6R expression in
cardiomyocytes, we found that IL-6 can induce a full complement of
MAPK and PI3K activation even in the absence of sIL-6R and STAT1/
STAT3 activation. This was in contrast to LIF which activated MAPK/
PI3K and JAK/STAT1/3. In the case of IL-6, JAK-STAT1/3 activation only
occurred in the presence of exogenously added sIL-6R. Furthermore,
Erk1/2 activation was both necessary and sufﬁcient for IL-6-induced
cytoprotection.2. Materials and methods
2.1. Materials
Recombinant murine IL-6 and LIF (I9646; L51558: endotoxinb1
EU/μg) and recombinant human erythropoietin (rhEPO: E5627) were
from Sigma, UK. Recombinant soluble IL-6 receptor (sIL-6R) was a gift
from Professor Peter Heinrich. Antibodies to phospho-STAT1 (Tyr701);
phospho-STAT3 (Tyr705); pan-STAT1; pan-STAT3; phospho-ERK1/2;
phospho-p38; phospho-JNK and phospho-PKB/Akt (Ser473) were
from Cell Signalling, UK. Antibodies to pan-p42-MAPK, pan-Erk1/2;
pan-p38 and pan-JNK were from Santa Cruz Biotech, USA. Antibodies
to iNOS (NOS2) were from BD-Transduction Labs, UK. Antibodies to
FLAG-epitope and α-actinin were from Sigma, UK. ALEXA-ﬂuor 568
goat-anti-mouse antibody and ToPro were from Molecular Probes, UK.
General purpose reagents were from Sigma-Aldrich, UK and Merck-
BDH, UK unless otherwise stated. Plasmid and RNA preparation
reagents were from Qiagen, UK. Collagenase was from Worthington
Biochemicals, USA. Pancreatin was from Gibco-BRL. Gelatin solution
was from Sigma, UK. Integrin-targeting peptide (peptide 6) was a gift
from Dr Stephen Hart, Institute of Child Health, UK and has been
described previously [19]. Lipofectin™ reagent was from Invitrogen,
UK. Creatine phosphokinase (CPK) assay kit was from Boehringer-
Mannheim, Germany. PD98059 and SB203580 were from Calbiochem,
UK.2.2. Isolated neonatal rat cardiomyocyte culture and treatment
All animal experimentswere performed in accordancewith Europe-
an Commission andUKHomeOfﬁce guidelines. Neonatal rat ventricular
cardiomyocytes (NRVMs/CMs)were isolated from1–2 day-old Sprague–
Dawley rats as previously described [20,21] by collagenase/pancreatin
digestion. Cells were plated at a density of approximately 2×106 cells
per well on gelatin coated 6-well plates (NUNC) in medium containing
4:1 DMEM:M199 supplemented with 5% foetal calf serum; 10% horse
serum and 1% penicillin/streptomycin (Gibco/BRL) for 24 h and then
transferred tomaintenancemedium (serum-free DMEM:M199 plus an-
tibiotics). Cells were maintained for 2 days in maintenance medium
(3 days after plating) prior to treatment. Cells were treated with
10–50 ng/ml sterile IL-6 or LIF reconstituted in 0.1% (w/v) BSA/PBS as
appropriate to the experiment for the indicated times. sIL-6R was
used at 100 ng/ml. IL-6 was complexedwith sIL-6R for 30 min inmain-
tenancemedium prior to addition. For inhibitor experiments cells were
pretreated with 50 μM PD98059, 10 μM SB203580 or vehicle (0.01%
DMSO) for 30 min prior to IL-6 or LIF application.
2.3. Transfections
Full length (Eg) and truncated (ΔB) gp130–EpoR fusion constructs
were transfected into cardiomyocytes using a Lipofectin-Integrin tar-
geting peptide–DNA (LID) protocol as previously described [19,22].
Full length (Eg) and truncated (ΔB) gp130–EpoR fusion constructs [23]
were sub-cloned into the pcDNA3.1 vector (Invitrogen, UK). They were
transiently expressed in CMs by overnight transfection using LID fol-
lowed by 72 h in serum free medium as previously described [19,22].
Subsequently CMs were treated with 100 ng/ml recombinant human
EPO (rhEPO) in serum free medium for 30 min (for harvesting for
phospho-immunoblots) or 24 h (for RNA isolation; for hypertrophy;
confocal analysis).
2.4. Simulated ischemia/reperfusion (sI/R)
sI/R was carried out using a modiﬁed Krebs buffer/anaerobic envi-
ronment protocol as described previously [18,21] and is a modiﬁca-
tion of the method described by Esumi et al. [24]. Brieﬂy, cells in
6-well tissue culture plates were exposed to 1.0 ml per well of sI buff-
er consisting of modiﬁed Krebs–Henseleit buffer containing (in mM):
137 NaCl; 12 KCl; 0.49 MgCl2; 1.8 CaCl2; 4 HEPES; 10 2-deoxyglucose;
20 Na lactate; pH 6.8. Cells were then exposed to a hypoxic environ-
ment by placing the plates into BBL GasPak anaerobic pouches
(Becton Dickinson, UK) for 6 h. Simulated reperfusion was achieved
by removing the plates from hypoxia and replacing the buffer with
1.0 ml of maintenance medium. The supernatant was then removed
after 3 h for analysis of creatine phosphokinase (CPK) release (as a
measure of cell injury).
2.5. Immunocytochemistry and confocal ﬂuorescence microscopy
Cardiomyocytes were plated on gelatin-coated chamber slides in
1.0 ml of medium. Following treatment samples were ﬁxed in 4%
paraformaldehyde for 10 min at room temperature (RT). Slides
were aspirated and left overnight in PBS at 4 °C. Slides were washed
for 3×5 min in PBS at RT then blocked for 1 h in PBS; 2% BSA; 2%
horse serum; 0.1% Triton x-100 at RT. Primary antibody was added
at 1:800 dilution in blocking buffer and incubated for 1 h at RT. Slides
were washed for 3×5 min in PBS; 0.1% Triton x-100 (PBST). FITC con-
jugated anti-mouse secondary antibody (Sigma) was added at 1:200
dilution in blocking buffer For 2 h at RT. Slides were washed for
3×5 min in PBST, aspirated, mounting medium added and cover-
slipped. Immunoﬂuorescence confocal microscopy was performed
using a Zeiss LSM 510 microscope. Where appropriate, the DNA
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Fig. 1. Differential signalling to JAK/STAT by IL-6 and LIF. Neonatal rat cardiomyocytes
were treated with IL-6 (with or without sIL-6R) or LIF for the indicated times (min) in
serum-free medium and harvested for Western Blot analysis. Blots were probed for:
Panels A and B: Phospho-STAT 1 (Tyr701); Phospho-STAT3 (Tyr705)/Total STAT3; Panel
C: Phospho-p38-MAPK (Thr180/Tyr182); Phospho-JNK (Thr183/Tyr185); Phospho-Erk1/
2 (Thr202/Tyr204)/Total Erk2.
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2.6. RT-PCR analysis
Following treatment RNA was extracted from cells using RNeasy
(Qiagen). RNA was reverse transcribed in 50 μl reactions using: 10 μl
5× ﬁrst strand buffer (Promega); 5 μl 0.1 M DTT; 1 μl oligo dT
(10 μg/ml); 1 μl random hexamers; 1 μl dNTPs (10 μg/ml); 28 μl
ddH2O; 3 μl total RNA. Samples were mixed, heated to 72 °C for
15 min [21] and cooled to RT. 1 μl RNase inhibitor and 1 μl reverse
transcriptase were added. RT was performed at 42 °C for 2–3 h.
cDNA was stored at−20 °C and 1 μl used for PCR reactions. PCR was
performed in 50 μl reactions using: 5 μl 10× buffer (5 mM MgCl2);
1 μl dNTPs (10 mM); 1 μl oligo A; 1 μl oligo B; 0.25 μl Taq polymerase;
40 μl ddH2O; 1.5 μl DNA; 0.25 μl DMSO. Primers usedwere as follows:
GAPDH: (forward) 5′-CACCATCTTCCAGGAGCGAG-3′; (reverse) 5′-
ACAGCCTTGGCAGC ACCAGT-3′; ANF: (forward) 5′-GTGAGCTTCCT
CCTTTTACTGG-3′; (reverse) 5′-AG GATGGACAGGATTGGAAATCA-3′;
SERCA2: (forward) 5′-GACGAGTTTGGGGAAC AGCT-3′; (reverse) 5′-
CAGGTGGTGATGACAGCAGG-3′.
3. Results
3.1. Differential JAK/STAT and MAPK/PI3K activation by IL-6 and LIF
Under basal conditions cardiomyocytes (CMs) express low levels
of IL-6R, but express the common IL-6 family cytokine receptor sig-
nalling component gp130 and also the ligand-binding domain of the
leukaemia inhibitory factor β (LIFRβ). However, IL-6R expression is
upregulated in CMs following stress, injury or neurohormonal activa-
tion [3,5,25]. We have shown previously that IL-6 induced PI3K- and
iNOS-dependent cytoprotection in CMs [18]. Therefore, we deter-
mined the requirement for MAPK and JAK/STAT activation by IL-6
and LIF under different conditions. Treatment of CMs with IL-6 or
LIF showed that only LIF but not IL-6 induced rapid and transient
STAT1 Tyr701 and STAT3 Tyr705 phosphorylation (Fig. 1A). However,
treatment of CMs with IL-6 in the presence of exogenously added sol-
uble IL-6R (sIL-6R) was able to reconstitute STAT1 Tyr701 and STAT3
Tyr705 phosphorylation (Fig. 1B). Furthermore, pre-treatment with
the p38-MAPK inhibitor SB203580 enhanced STAT1 and STAT3 phos-
phorylation by IL-6/sIL-6R (Fig. 1B). This is consistent with negative
regulation of STAT3 activation by p38-MAPK/MK2-dependent phos-
phorylation of gp130 Ser782 [26] and suggests that Ser782 is constitu-
tively phosphorylated by p38-MAPK/MK2 in CMs in the absence of
sIL-6R.
The phosphorylation of STAT1 and STAT3 requires JAK1/
2-dependent phosphorylation of critical tyrosine residues within
the membrane distal gp130 cytoplasmic domain which are then
able to recruit the STATs via their SH2 domains. However, Tyr757
within the membrane proximal region is thought to be required for
MAPK activation via recruitment of SHP2. Furthermore, two proximal
juxtamembrane regions termed Box 1 and Box 2 are sufﬁcient for
JAK1 and JAK2 recruitment. Given that the results above suggest
that IL-6 cannot recruit and activate STAT1 and STAT3 in the absence
of sIL-6R, we analysed the activation of MAPKs (Erk1/2, p38 and JNK)
in response to IL-6 and LIF. Surprisingly, IL-6 (in the absence of
sIL-6R) and LIF induced equivalent phosphorylation of Erk, JNK and
p38-MAPK (Fig. 1C). Taken together, these results demonstrate that
IL-6 can induce a distinct pattern of signalling in the absence of
sIL-6R and gp130-dependent JAK/STAT1/3 activation.
3.2. MAPK-dependent protection against simulated ischemia
Both gp130- dependent MAPK and JAK/STAT activation have been
implicated in cardiomyocyte survival. Since we have previouslyshown that IL-6 can induce CM survival [18] and IL-6 can induce
PI3K/PKB activation independently of JAK/STAT activation, we com-
pared IL-6 and LIF in their ability to protect CMs against simulated
ischaemia/reperfusion injury (sI/R) using creatine phosphokinase (CPK)
release as an index of injury. Both IL-6 and LIF pre-treatment 24 h before
sI/R induced an equivalent reduction in sI/R injury (Fig. 2). To determine
whether protection was p42/p44-MAPK (Erk1/2) or p38-MAPK-
dependent, IL-6 and LIF pre-treatment were performed in the presence
of pathway-selective pharmacological inhibitors. Interestingly, PD98059
(MEK1/2 inhibitor) reversed protection. In contrast, SB203580 (p38-
MAPK inhibitor) had no effect. The efﬁcacy of PD98059 to block Erk1/2
phosphorylation is shown in panel C. In keeping with our previous
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Fig. 2. Erk dependent protection induced by IL-6 and LIF. Neonatal rat cardiomyocytes
were treated with IL-6 (50 ng/ml) or LIF (10 ng/ml) in the presence of vehicle (DMSO)
or PD98059 (50 μM), or SB203580 (10 μM) for 24 h in serum-free medium and then
subjected to simulated ischemia/reoxygenation (sI/R) injury for 2 h. Cell injurywas deter-
mined by assay of CPK release into the supernatant (Abs at 340 nm) after 3 h of
reoxygenation expressed as % of sI/R (set to 100%). Results are expressed as mean±
SEM for triplicate experiments (n=3)each performed in triplicate. Statistically signiﬁcant
differences are indicated as ***pb0.001 vs sI/R or ††† vs vehicle Panel A: IL-6
pre-treatment; Panel B: LIF pre-treatment. Panel C: Western blots of Phospho-Erk1/2
(top) and total Erk2 (bottom) demonstrating the efﬁcacy of PD98059 to inhibit phosphor-
ylation of the respective downstream kinases.
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PI3K-dependent protection independently of JAK/STAT and that MAPK/
PI3K activation are both necessary and sufﬁcient for protection in this
context.
3.3. iNOS/nitric oxide induction by IL-6 and LIF
We have previously reported that IL-6-induced protection of CMs is
dependent on iNOS-derived nitric oxide (NO) [18]. Therefore, we
analysed the expression of iNOS and NO-production in CMs following
pre-treatment with the α1-adrenergic receptor (α1-AR) agonist phenyl-
ephrine (PE), IL-6 and LIF. The inﬂammatory (Toll-like receptor) agonist
bacterial lipopolysaccharide (LPS) was used as a positive control. Fig. 3
shows that PE and IL-6 but not LIF induced strongNOproduction as deter-
mined using the ﬂuorescent NO probe DAF2-DA. In keeping with this, PE
and IL-6 but not LIF, induced upregulation of iNOS expression. We have
previously shown that IL-6-induced protection was iNOS-dependent,
since when CMs were treated with the selective iNOS inhibitor amino
guanidine (AG) prior to sI/R [18], AG blocked IL-6-induced protection.
3.4. IL-6 and LIF-dependent cardiomyocyte hypertrophy
The IL-6 family of gp130-dependent cytokines including IL-6, LIF
and CT-1 have been implicated in CM hypertrophy and heart failure.
Furthermore, Erk1/2 and PI3K/PKB play a role in adaptive hypertro-
phy [15,16]. The role of JAK/STAT activation in hypertrophy is less
clear, but STAT3 may play a role in gp130-dependent hypertrophy
[27–29]. Because IL-6 family cytokines activate the Erk1/2, PI3K/PKB
and JAK/STAT axes concomitantly, their individual contribution to hy-
pertrophy is complex. We compared the ability of IL-6, LIF and PE to
induce hypertrophy in isolated cultured neonatal rat ventricular
cardiomyocytes (NRVMs) as determined by changes in morphological
characteristics such as cell size and myoﬁlament organisation, staining
with CM-speciﬁc markers and gene expression. Fig. 4A shows that
IL-6 and LIF both induced CM hypertrophy at 24 h as shown by in-
creased cell size and elaboration of myoﬁlaments as visualised by
α-actinin staining. Both IL-6- and LIF-induced hypertrophy were asso-
ciated with a reorganisation of myoﬁlaments from a linear pattern
aligning with the long axis of the cell to a radial pattern accompanied
by increased stress ﬁbre formation. Interestingly, the intensity of
staining for the Z-disc marker α-actinin and the ECM marker laminin
were reduced in LIF-treated cells compared to IL-6 or PE. This suggests
that there are phenotypic differences between the IL-6- and LIF-
induced hypertrophy.
Since IL-6 and LIF appear to induce equivalent but distinct patterns
of hypertrophy in CMs, we analysed the expression of hypertrophy-
associated gene markers in response to PE, IL-6 and LIF, including atrial
natriuretic factor (ANF) and the sarcoplasmic reticulum calcium pump
SERCA2a. The results shown in Fig. 4B demonstrate that PE, IL-6 and
LIF induced similar increases in myocyte area. In contrast, differential
expression of ANF and SERCA2a were observed. Whereas PE induced
strong upregulationANFmRNA, IL-6 and LIF both inducedweak expres-
sion of ANF. Furthermore, PE and IL-6 did not induce SERCA2 expres-
sion, whereas LIF induced strong SERCA2a mRNA expression.
3.5. Requirement for proximal versus distal gp130 regions
Because IL-6 and LIF induce similar but distinct responses in CMs
(and distinct patterns of JAK/STAT activation) we next determined the
requirement for the proximal and distal regions of gp130 in these re-
sponses. CMs were transfected with fusion constructs consisting of the
full length, epitope-tagged cytoplasmic domain of gp130 coupled to
the erythropoietin receptor (EpoR) extracellular ligand-binding domain
(referred to as Eg) or a truncated gp130 containing only the Box 1 and
Box 2 regions (referred to as ΔB) as depicted in Fig. 5A [23]. EpoR
C PE IL-6
LIF LPS
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iNOS
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Fig. 3. Analysis of nitric oxide/iNOS expression. Panel A: Fluorescence micrographs of neonatal rat cardiomyocytes loaded with DAF-2DA. Cells were treated with Phenylephrine
(PE: 10 μM), IL-6 (50 ng/μl), LIF (50 ng/μl) and LPS (10 μM) for 24 h in serum-free medium. Control myocytes (C) were left untreated. Panel B: Western blot containing 60 μg
of protein per lane from control and treated cardiomyocytes immunoblotted with anti-iNOS antibody.
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EpoR has been reported to be expressed in CMs and mediate cardio-
protection [30,31]. However, both the presence of EpoR itself and the
speciﬁc molecular determinants of EpoR-protective mechanisms in
CMs have recently been challenged [32–34]. Nevertheless, the possible
presence of endogenous EpoR coupled to gp130 in the system is a possi-
ble confounder. However, treatment of CMswith EPO alone (100 ng/ml)
did not elicit a signiﬁcant response under control conditions (null vec-
tor). Therefore, ﬁrstly, we analysed the ability of these constructs to in-
duce activation of STAT1 and STAT3 phosphorylation in response to
exogenously added EPO. As expected, both STAT1 and STAT3 phosphor-
ylationwere increased in the Eg but not theΔB expressing cells (Fig. 5B).
In factΔB appeared to have a slightly dominant negative effect on STAT1
phosphorylation and STAT3 expression. Erk1/2 and PKB(Akt) phosphor-
ylation were intact in ΔB expressing cells, suggesting that sites within
Box 1 and Box 2 are sufﬁcient for Erk1/2 and PI3K activation.
These results conﬁrm the ﬁdelity of themodel in the absence of a sig-
niﬁcant effect of EPO on endogenous pathways. Equivalent expression of
Eg andΔBwas conﬁrmed by blottingwith anti-FLAGantibodies (Fig. 6A).
Interestingly, both Eg andΔB induced identical increases inmyocyte areaFig. 4. Analysis of hypertrophic cell morphology and gene markers. Panel A: Confocal ﬂuore
(green), laminin (red) and DAPI (blue) following treatment with Phenylephrine (10 μM), I
sents untreated myocytes (control). Magniﬁcation 40×. Panel B: mean cell area±SEM (n=
24 h in serum free medium. Cell area was analysed with using Adobe Photoshop. Statistical
RT-PCR of untreated (control) and neonatal rat cardiomyocytes treated (as above) for 12 h
hypertrophic markers, ANF and SERC2a. GAPDH was used as a housekeeping control.and SERCA2mRNAexpression (Fig. 6B), indicating that STAT1 and STAT3
phosphorylation are dispensible for gp130-dependent hypertrophy. We
further analysed the NO production in CMs expressing Eg and ΔB. Fig. 7
shows that both Eg andΔB induced similar increases inNOproduction as
determined by confocal analysis of DAF2-DA-loaded CMs. This was also
associated with similar induction of iNOS expression in Eg and ΔB ex-
pressing CMs (Fig. 6A).
4. Discussion
These studies show that STAT1 and STAT3 phosphorylation are
dispensible for the induction of hypertrophy and iNOS-dependent sur-
vival of cardiomyocytes. We have identiﬁed a minimal IL-6 signalling
modality in CMs which only requires the membrane proximal region
of gp130. Nevertheless, it remains to be determined how IL-6, or indeed
the minimal gp130ΔB construct signals to Erk1/2 and PI3K/Akt. Signal-
ling of IL-6 via gp130would be expected to be associatedwith JAK/STAT
activation, since JAKs are constitutively associated with the gp130β
chain [11,35]. The activation of the Erk/MAPK and PI3K axes in this
study appeared to be maximal despite the absence of STAT1/3scence micrographs of neonatal rat ventricular cardiomyocytes stained with α-actinin
L-6 (50 ng/ml), LIF (50 ng/ml) for 24 h in serum-free medium. The upper panel repre-
200) of untreated (control) and neonatal rat cardiomyocytes treated (as above) for
analysis was performed using Student's t-test. **pb0.05 versus control. Representative
in serum-free medium. RT-PCR was performed using oligonucleotide primers for the
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Fig. 5. Analysis of JAK/STAT, MAPK and PI3K Activation by gp130. Panel A: Schematic representation of FLAG-tagged full length (Eg) and truncated (ΔB) gp130–EpoR fusion con-
structs showing the EpoR extracellular ligand binding domain (hatched), the membrane-spanning region and the cytoplasmic domain. Box 1 and Box 2 JAK binding domains are
shown (shaded) and the phosphotyrosine residue docking sites for STATs are indicated. Panel B: Neonatal rat cardiomyocytes were transfected with pcDNA3.1, Eg and ΔB for 72 h
in serum-free medium and subsequently stimulated with 100 ng/ml EPO for 30 min and harvested for Western Blot analysis. Blots were probed for Phospho-STAT 1 (Tyr701)/Total
STAT1; Phospho-STAT3 (Tyr705)/Total STAT3; Phospho-Erk1/2 (Thr202/Tyr204)/Total Erk1/2; Phospho-Akt (PKB: Ser473)/Total Akt(PKB).
904 A. Fahmi et al. / Cellular Signalling 25 (2013) 898–909phosphorylation. It is possible that MAPK/PI3K activation has a lower
threshold. Activation of the Erk1/2 cascade via gp130 is thought to re-
quire recruitment of the SH2 containing cytolplasmic protein tyrosine
phosphatase SHP2. Phosphorylation of the membrane proximal Tyr757
is necessary and sufﬁcient for SHP2 recruitment. Tyr phosphorylation ofSHP2 leads to activation of the Ras/Erk1/2 module through recruitment
of the Grb2/Sos docking protein/RasGTP exchange factor complex
[11,35]. SHP2 can also form a complex with the scaffolding proteins
Gab1/2 and the p85 subunit of PI3K, thus leading to activation of the
PI3K pathway and ERK5 [36]. Also, activated STAT5A and B can form a
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serum-free medium and subsequently stimulated with 100 ng/ml EPO. Cells were harvested for Western blotting 24 h after EPO treatment. Blots were probed with anti-FLAG or
anti-iNOS antibodies. Panel B: Mean cell area±SEM (n=100) of neonatal rat cardiomyocytes transfected with pcDNA3.1 (empty vector), Eg or ΔB for 72 h in serum-free medium
and subsequently stimulated with 100 ng/ml EPO. Cells were ﬁxed and micrographed after 24 h of EPO treatment. Cell area was analysed using Adobe Photoshop. Statistical anal-
ysis was performed using a student's t-test. *pb0.05 versus pcDNA3.1. Below is shown representative RT-PCR of transfected neonatal rat cardiomyocytes which have been cultured
for 72 h in serum-free medium and subsequently stimulated with EPO for 6 h. RNA was extracted and RT-PCR was performed using oligonucleotide primers for hypertrophic
markers ANF and SERC2a. GAPDH was used as a housekeeping control.
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PI3K activation, which is independent of SHP2 [12]. Mutation of
Tyr757 to Phe has been shown to block Erk1/2 activation [37].
However, this paradigm does not explain our results unless
JAK-dependent Tyr757 phosphorylation and SHP2 recruitment versusdistal Tyr phosphorylation and STAT1/3 recruitment are mutually in-
dependent events. Even so, the gp130ΔB construct is truncated
N-terminal to Tyr757 [23]. However, it has been reported that JAK2
can also activate Erk1/2 and PI3K/Akt independently of SHP2
[12,13]. This latter mechanism could explain our results if IL-6
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Fig. 7. Analysis of gp130-dependent changes in hypertrophic cell morphology and NO production. Confocal ﬂuorescence micrographs of neonatal rat ventricular cardiomyocytes
stained with α-actinin (red), DAF2-DA (green) and ToPro (blue) following transfection with pcDNA3.1 (empty vector), Eg or ΔB for 72 h in serum-free medium and subsequently
stimulated with 100 ng/ml EPO. Cells were loaded with DAF2-DA and/or ﬁxed for staining and confocal analysis 24 h after EPO treatment.
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activation, this could also be achieved, at least in part, by negative feed-
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sally represses STAT1/3 phosphorylation via Ser782 phosphorylation of
gp130monomerswhich leads to gp130 internalisation and degradation
[26]. Thus the absence of STAT1/3 phosphorylation may be due to
low endogenous levels of the cIL-6Rα, whereas stabilisation of
gp130 homodimers in the presence of sIL-6R is able to overcome
this.
There is further evidence that a balance exists between JAK/STAT
and Erk1/2 activation and that Erk1/2 activation may also act to
prevent sustained STAT3 activation [11]. STAT3 activation in itself
appears to play an important, although complex role in cardiomyo-
cyte survival and remodelling. For instance, overexpression of the
negative regulator of gp130/STAT signalling, suppressor of cytokine
signalling 1 (SOCS1) promotes the transition to heart failure in a
model of pressure overload [38]. Conversely, CM-restricted knockout
of SOCS3 prevents post-MI remodelling [39] but increases SR Ca2+
overload, cardiac dysfunction and arrhythmias [40]. The SHP2/Erk1/2
axis may also negatively regulate gp130/STAT activation because mice
lacking gp130Y757 develop various organ defects resulting from over-
activation of gp130/STAT1/3, since Tyr757 is also necessary for recruit-
ment of SOCS3. In addition, STAT1 and STAT3 may have opposing
roles in CM survival, since STAT1 has been shown to promote CM apo-
ptosis [41,42].
Since it is well established that Erk1/2 and PI3K/Akt can cooperate to
mediate CM survival [18,21], it is not surprising that our results show
that activation of these pathways can protect CMs in the absence of
JAK/STAT activation. However, our results do not preclude a protective
role for STAT3 in other contexts and likewise do not preclude a role
for STAT3 in myocardial hypertrophy and myoﬁlament remodelling
in vivo in response to complex stimuli comprising biomechanical stresses
and neurohumoral and/or cytokine activation. For instance, STAT3 over-
expression alone induces CM hypertrophy in vitro and in vivo [9,27,28].
STAT3 has also been shown to have positive effects on CM survival
which may be independent of its function as a transcription factor (i.e.
non-genomic) and act at the mitochondrial level [43]. Furthermore, re-
cent evidence suggests that pharmacological inhibition of STAT3 but not
STAT1 reduced collagen deposition and cardiac ﬁbrosis in a model of
renal artery ligation in rats. This was accompanied by reduced cardiac
hypertrophy, reduced re-expression of foetal genemarkers and improved
cardiac function [44]. This suggests that STAT3 may play an important
role in cardiac remodelling driven by IL-6/STAT3 activation in cardiac
ﬁbroblasts. Interestingly, inhibition of p38-MAPK showed similar effects,
showing that p38-MAPK activation is also pro-ﬁbrotic.
There may also be important compartmental considerations in
relation to the role of JAK/STAT signalling in myocardial remodelling.
For instance, Lindner et al. 45] found that STAT3 knockout mice
showed reduced cardiac function and increased collagen deposition
in a model of cocksackie virus-induced myocarditis. Importantly, this
was a cardiomyocyte-restricted knockout. Therefore, they conclude
that STAT3 signalling in CMs protects against ﬁbrosis. Furthermore,
cardiomyocyte-speciﬁc knockout of STAT3 induces age-dependent
heart failure [46]. Therefore activation of STAT3 in cardiomyocytes
versus myoﬁbroblasts may have opposite effects on ﬁbrosis and CM
hypertrophy. In support of our results, Szabo-Fresnais et al. recently
reported that IL-6 activates Erk1/2 and PI3K signalling in adult rat
cardiomyocytes in the absence of JAK/STAT activation via a cognate re-
ceptor [6]. Therefore, it seems highly likely that CMs do express a cog-
nate receptor of some form, but how differential activation of Erk1/2
MAPK and PI3K independent of JAK/STAT is achieved remains to be de-
termined. A diagram depicting the possible modes of IL-6/LIF receptor/
gp130 activation is shown in Fig. 8.
In conclusion, our results show that IL-6 has important pro-
survival effects in cardiomyocytes which are mediated by Erk1/2 and
PI3K/Akt activation and which are independent of gp130-dependent
JAK/STAT activation. Furthermore, Erk1/2 and PI3K/Akt activation ap-
pear to be necessary and sufﬁcient for cardiomyocyte hypertrophyinduced by IL-6, or by a minimal gp130 construct containing only the
membrane-proximal Box 1 and Box 2 regions.
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